Abstracts Archive - Page 2052 of 2425 - ACR Meeting Abstracts

Abstract Number: L17 • 2014 ACR/ARHP Annual Meeting
Bariatric Surgery Improves Rheumatoid Arthritis Disease Activity, Reduces Inflammatory Markers, and Decreases Medication Usage
Jeffrey A. Sparks¹, Florencia Halperin², Jonathan C. Karlson³, Elizabeth W. Karlson¹ and Bonnie L. Bermas¹, ¹Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ²Division of Endocrinology, Diabetes and Hypertension, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ³Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA
Background/Purpose: Obesity causes a chronic inflammatory state. Increased body mass index (BMI) is associated with incident rheumatoid arthritis (RA) and may impact RA disease activity.…
Abstract Number: L1 • 2014 ACR/ARHP Annual Meeting
Secukinumab, a Human Anti-Interleukin-17A Monoclonal Antibody, Improves Active Psoriatic Arthritis: 24-Week Efficacy and Safety Data from a Phase 3 Randomized, Multicenter, Double-Blind, Placebo-Controlled Study Using Subcutaneous Dosing
Iain B. McInnes^1,2, Philip J. Mease³, Bruce Kirkham⁴, Arthur Kavanaugh⁵, Christopher T. Ritchlin⁶, Proton Rahman⁷, Désirée van der Heijde⁸, Robert B. M. Landewé⁹, Philip G. Conaghan¹⁰, Hanno Richards¹¹, Gregory Ligozio¹², Luminita Pricop¹³ and Shephard Mpofu¹⁴, ¹University of Glasgow, Glasgow, Scotland, ²University of Glasgow, Glasgow, United Kingdom, ³Swedish Medical Center and University of Washington, Seattle, WA, ⁴Guy’s and St Thomas’ NHS Foundation Trust, London, United Kingdom, ⁵UC San Diego School of Medicine, La Jolla, CA, ⁶Allergy Immunology & Rheumatology, University of Rochester Medical Center, Rochester, NY, ⁷Memorial University, St John's, NF, Canada, ⁸Leiden University Medical Center, Leiden, Netherlands, ⁹University of Amsterdam and Atrium Medical Center, Amsterdam, Netherlands, ¹⁰University of Leeds, Leeds, United Kingdom, ¹¹Clinical Immunology / Dermatology, Novartis Pharma AG, Basel, Switzerland, ¹²Novartis Pharmaceuticals Corporation, East Hanover, NJ, ¹³Integrated Hospital Care (IHC) Franchise, Novartis Pharmaceuticals Corporation, East Hanover, NJ, ¹⁴Novartis Pharma AG, Basel, Switzerland
Background/Purpose: Secukinumab, a human anti–IL-17A monoclonal antibody, has shown efficacy in the treatment of psoriasis in phase 3 studies with subcutaneous (s.c.) dosing as well…
Abstract Number: L6 • 2014 ACR/ARHP Annual Meeting
A PHASE 2, Randomized, Double-Blind Comparison of the Efficacy and Safety of PF-04171327 (1, 5, 10, 15 mg QD) Vs 5 and 10 Mg Prednisone QD or Placebo in Subjects with Rheumatoid Arthritis (RA) over 8 Weeks Followed By a 4-Week Taper of Study Drug
Vibeke Strand¹, Frank Buttgereit², Dorothy McCabe³, Sheela Kolluri³, Brinda Tammara³, Ricardo Rojo³ and Judith Hey-Hadavi^3,4, ¹Biopharmaceutical Consultant, Portola Valley, CA, ²Charité University Hospital, Berlin, Germany, ³Pfizer Inc, New York, NY, ⁴Pfizer Inc, NewYork, NY
Background/Purpose: PF-04171327 is a dissociated agonist of the glucocorticoid receptor (DAGR), a selective high-affinity partial agonist of the GR with potent anti-inflammatory activity at exposures…
Abstract Number: L5 • 2014 ACR/ARHP Annual Meeting
Improvement of Disease Activity and Reduction of Severe Flares Following Subcutaneous Administration of an IL-6 Monoclonal Antibody (mAb) in Subjects with Active Generalized Systemic Lupus Erythematosus (SLE)
Daniel J Wallace¹, Serghei Popa², Alberto J. Spindler³, Alicia Eimon⁴, Tania González-Rivera⁵, Tammy O. Utset⁶, Michelle Petri⁷, Peter E. Lipsky⁸, Joan T. Merrill⁹, Vibeke Strand¹⁰, Joseph Wajdula¹¹, Jared Christensen¹², Cheryl Li¹³, Annette Diehl¹¹, Michael Vincent¹⁴, Jean Beebe¹² and Sudhakar Sridharan¹¹, ¹Cedars-Sinai Medical Center, Los Angeles, CA, ²Arensia Exploratory Medicine, Chisinau, Moldova, ³Centro Medico Privado de Reumatologia, Tucuman, Argentina, ⁴CEMIC, Buenos Aires, Argentina, ⁵Department of Medicine, Division of Rheumatology, University of Michigan School of Medicine, Ann Arbor, MI, ⁶University of Chicago, Chicago, IL, ⁷Johns Hopkins Lupus Center, Johns Hopkins University School of Medicine, Baltimore, MD, ⁸AMPEL BioSolutions, Charlottesville, VA, ⁹Department of Clinical Pharmacology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ¹⁰Stanford University, Palo Alto, CA, ¹¹Global Innovative Pharma Business, Pfizer Inc, Collegeville, PA, ¹²BioTherapeutics Clinical R&D, Pfizer Inc, Cambridge, MA, ¹³Pfizer Inc, Cambridge, MA, ¹⁴BioTx Clinical R&D, Pfizer Inc, Cambridge, MA
Background/Purpose: PF-04236921 is a fully human mAb that binds to circulating IL-6 and neutralizes its activity. This may be beneficial in reducing the disease…
Abstract Number: L4 • 2014 ACR/ARHP Annual Meeting
Safety and Efficacy of Sifalimumab, an Anti IFN-Alpha Monoclonal Antibody, in a Phase 2b Study of Moderate to Severe Systemic Lupus Erythematosus (SLE)
Munther Khamashta^1,2, Joan T. Merrill³, Victoria P. Werth^4,5, Richard Furie⁶, Kenneth Kalunian⁷, Gabor G. Illei⁸, Jorn Drappa⁸, Liangwei Wang⁸ and Warren Greth⁸, ¹Division of Women's Health, Graham Hughes Lupus Research Laboratory, King's College London, London, United Kingdom, ²Lambeth Wing, The Rayne Institute, St Thomas' Hospital London, London, United Kingdom, ³Clinical Pharmacology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁴Philadelphia VA Medical Center, Philadelphia, PA, ⁵University of Pennsylvania, Philadelphia, PA, ⁶North Shore-LIJ Health System, Lake Success, NY, ⁷UCSD School of Medicine, La Jolla, CA, ⁸MedImmune, LLC, Gaithersburg, MD
Background/Purpose: Efficacy and safety of sifalimumab were assessed in a Phase 2b, randomized, double-blind, placebo (PBO)-controlled study in subjects with SLE (NCT01283139). Methods: Adults (n=431)…
Abstract Number: L2 • 2014 ACR/ARHP Annual Meeting
A Comparison of Three Treatment Strategies in Recent Onset DMARD Naïve Juvenile Idiopathic Arthritis: 3-Months Results of the BeSt for Kids-Study
Petra C.E. Hissink Muller^1,2, D.M.C. Brinkman^1,3, Dieneke Schonenberg⁴, Yvonne Koopman-Keemink⁵, J. Merlijn Van den Berg⁶, W.P. Bekkering⁷, Marion van Rossum^8,9, Lisette WA van Suijlekom-Smit¹⁰, Cornelia F. Allaart¹¹ and Rebecca ten Cate¹, ¹Pediatric Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ²Pediatric Rheumatology, Reade, Amsterdam, Netherlands, ³Pediatric Rheumatology, Rijnland Hospital, Leiderdorp, Netherlands, ⁴Department of Pediatric Rheumatology and Immunology, Emma Children's Hospital, Academic Medical Center, Amsterdam, Netherlands, ⁵Pediatrics, Haga ziekenhuis, The Hague, Netherlands, ⁶Pediatric Hematology, Immunology and Infectious diseases, Emma Children's Hospital, Academic Medical Center, Amsterdam, Netherlands, ⁷Pediatric Physiotherapy, Leiden University Medical Center, Leiden, Netherlands, ⁸Pediatric Rheumatology Immunology, Emma Children's Hospital, Academic Medical Center, Amsterdam, Netherlands, ⁹Reade, Amsterdam, Netherlands, ¹⁰Pediatric Rheumatology, Sophia Children's Hospital Erasmus Medical Center, Rotterdam, Netherlands, ¹¹Rheumatology, Leiden University Medical Center, Leiden, Netherlands
Background/Purpose: BeSt for Kids compares 3 Disease Modifying Anti Rheumatic Drug (DMARD) strategies in juvenile idiopathic arthritis (JIA) patients, for time to inactive disease, time…
Abstract Number: L13 • 2014 ACR/ARHP Annual Meeting
Monthly Ibandronate Reduces Bone Loss in Osteopenic Women with Rheumatoid Arthritis Receiving Long-Term Glucocorticoids: A 48-Week Double-Blinded Randomized Placebo-Controlled Investigator-Initiated Trial
Kichul Shin¹, Sung-Hwan Park², Won Park³, Han Joo Baek⁴, Yun Jong Lee⁵, Seong-Wook Kang⁶, Jung-Yoon Choe⁷, Wan-Hee Yoo⁸, Yong-Beom Park⁹, Jung-Soo Song¹⁰, Bin Yoo¹¹, Dae-Hyun Yoo¹² and Yeong Wook Song¹³, ¹Rheumatology, SMG-SNU Boramae Medical Center, Seoul, South Korea, ²Division of Rheumatology, Department of Internal Medicine, Seoul St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul, South Korea, ³Medicine/Rheumatology, Inha University Hospital, Incheon, South Korea, ⁴Division of Rheumatology, Department of Internal Medicine, Gachon University Gil Medical Center, Incheon, South Korea, ⁵Division of Rheumatology, Department of Internal Medicine, Seoul National University College of Medicine, Seoul, South Korea, ⁶Department of Internal Medicine, Chungnam National University School of Medicine, Daejeon, South Korea, ⁷Division of Rheumatology, Catholic University of Daegu School of Medicine, Daegu, South Korea, ⁸Department of Internal Medicine, Chonbuk National University Medical School and Research Institute of Clinical Medicine, Jeonju, South Korea, ⁹Division of Rheumatology, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, South Korea, ¹⁰Rheumatology, Chung-Ang Univ Hospital, Seoul, South Korea, ¹¹Division of Rheumatology, Department of Internal Medicine, University of Ulsan College of Medicine, Asan Medical Center, Seoul, South Korea, ¹²Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea, ¹³Department of Molecular Medicine and Biopharmaceutical Sciences, BK 21 plus Graduate School of Convergence Science and Technology, and College of Medicine, Seoul National University, Seoul, South Korea
Background/Purpose: Long-term use of glucocorticoids (GC) is problematic for patients with increased risk for vertebral fractures, especially those with rheumatoid arthritis (RA). Thus, prevention of…
Abstract Number: L11 • 2014 ACR/ARHP Annual Meeting
Raman Spectroscopy: Point of Service Diagnosis Is Sensitive and Specific-a Tool for Improving Accuracy and Reducing Future Hospital Admission
Nora Singer¹, Bolan Li², Yener Yeni³, Emma Barnboym⁴, Steven Lewis⁵, Daniel Oravec⁶, Donald Haggins⁷ and Ozan Akkus², ¹Rheumatology, MetroHealth Medical Center and CWRU, Cleveland, OH, ²Mechanical and Aerospace Engineering, Case Western Reserve University, Cleveland, OH, ³Section of Biomechanics, Bone and Joint Cetner, Henry Ford Hospital, Detroit, MI, ⁴Rheumatology, MetroHealth Medical Center, Cleveland, OH, ⁵Medicine, MetroHealth Medical Center, Cleveland, OH, ⁶Bone and Joint Center, Henry Ford Hospital, Detroit, MI, ⁷Rheumatology, Henry Ford Hospital, Detroit, MI
Background/Purpose: The diagnosis of gout or pseudogout hinges upon identification of monosodium urate (MSU) crystals and calcium pyrophosphate (CPPD) crystals in synovial fluid (SF) aspirates…
Abstract Number: L9 • 2014 ACR/ARHP Annual Meeting
Contrast Enhanced Ultrasonography in Patients Diagnosed with Early Arthritis: A Preliminary Experience
Maria-Magdalena Tamas¹, Nicolae Rednic², Ana Petcu¹, Cosmina Ioana Bondor³, Horatiu Popoviciu⁴, Eugenia Mociran⁵ and Simona Rednic¹, ¹Department of Rheumatology, "Iuliu Hatieganu" University of Medicine and Pharmacy Cluj-Napoca, Cluj-Napoca, Romania, ²4th Medical Clinic Cluj-Napoca, Cluj-Napoca, Romania, ³Department of Medical Informatics and Biostatistics, "Iuliu Hatieganu" University of Medicine and Pharmacy Cluj-Napoca, Cluj-Napoca, Romania, ⁴Rheumatology, University of Medicine and Pharmacy Targu Mures, Tg Mures, Romania, ⁵Rheumatology, Policlinica "Sf. Ioan" Baia Mare, Baia Mare, Romania
Background/Purpose: The role of ultrasonography (US) in early rheumatoid arthritis (ERA) for detecting synovial hypertrophy and its vascularity has already been demonstrated. Contrast enhanced ultrasonography…
Abstract Number: L18 • 2014 ACR/ARHP Annual Meeting
14-3-3eta Informs Joint Pathological Mechanisms of Treatment Response to Assist with T2T Strategies
Shintaro Hirata¹, Kentaro Hanami², Anthony Marotta³ and Yoshiya Tanaka⁴, ¹The First Department of Internal Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan, ²The first department of Internal Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan, ³1423 Dempsey Road, Augurex Life Sciences Corp., North Vancouver, BC, Canada, ⁴University of Occupational and Environmental Health, Japan, Kitakyushu, Japan
Background/Purpose: A primary clinical goal of RA in treating to target (T2T) is to improve long term outcomes including the control of symptoms and prevention…
Abstract Number: L19 • 2014 ACR/ARHP Annual Meeting
Randomized Trial of Stopping TNF-Inhibitors in Rheumatoid Arthritis Patients with Stable Low Disease Activity in the Netherlands
Harald E. Vonkeman¹, Marjan Ghiti Moghadam², Mart A.F.J. van De Laar³, Peter M. ten Klooster⁴, Tim Jansen⁵ and Piet van Riel⁶, ¹Rheumatology, Medisch Spectrum Twente, Enschede, Netherlands, ²rheumatology, Enschede, Netherlands, ³Rheumatology, Medisch Spectrum Twente & University of Twente, Enschede, Netherlands, ⁴Psychology, Health & Technology, University of Twente, Enschede, Netherlands, ⁵Rheumatology, Radboud University Medical Center, Nijmegen, Netherlands, ⁶Rheumatology, Nijmegen, Netherlands
Background/Purpose: The effectiveness of TNF-inhibitors (TNFi) in the treatment of rheumatoid arthritis has already been demonstrated in many studies. However, little is known on stopping…
Abstract Number: L10 • 2014 ACR/ARHP Annual Meeting
Lesinurad, a Novel Selective Uric Acid Reabsorption Inhibitor, in Two Phase III Clinical Trials: Combination Study of Lesinurad in Allopurinol Standard of Care Inadequate Responders (CLEAR 1 and 2)
Kenneth G. Saag¹, Scott Adler², Nihar Bhakta³, Maple Fung³, Jeff Kopicko³, Chris Storgard³ and Thomas Bardin⁴, ¹Immunology & Rheumatology, The University of Alabama at Birmingham, Birmingham, AL, ²AstraZeneca Pharmaceuticals, Wilmington, DE, ³Ardea Biosciences, Inc., San Diego, CA, ⁴Clinique de Rhumatologie. Service de Rhumatologie. Centre Viggo Petersen., Hôpital Lariboisière, Paris, France
Background/Purpose: Inadequate response to allopurinol monotherapy is common. Lesinurad (RDEA594) is a selective uric acid reabsorption inhibitor (SURI) under investigation for treatment of gout in…
Abstract Number: L24 • 2014 ACR/ARHP Annual Meeting
A Progressive Increase in T Follicular Helper Cells Marks the Transition from Benign to Symptomatic Autoimmunity
Sina Rusta-Sallehy¹, Babak Noamani², Dennisse Bonilla³, Nan-Hua Chang⁴, Larissa Lisnevskaia⁵, Sindhu R. Johnson⁶, Earl Silverman⁷, Arthur A. M. Bookman⁸, Joan E. Wither⁹ and Carolina Landolt-Marticorena³, ¹Medicine, University of Toronto, Toronto, ON, Canada, ²Genetics and developmental biology, Toronto Western Research Institute, Toronto, ON, Canada, ³Rheumatology, Toronto Western Hospital, Toronto, ON, Canada, ⁴Genetics and Development, Toronto Western Research Institute, Toronto Western Hospital, Toronto, ON, Canada, ⁵Rheumatology, Lakeridge Health Center, Toronto, ON, Canada, ⁶Medicine, Toronto Scleroderma Program, Toronto Western Hospital, Toronto General Hospital, Mount Sinai Hospital, and University of Toronto, Toronto, ON, Canada, ⁷Division of Rheumatology, Hosp for Sick Children, Toronto, ON, Canada, ⁸Division of Rheumatology, Toronto Western Hospital (UHN), Toronto, ON, Canada, ⁹Toronto Western Research Institute, Toronto Western Hospital, Toronto, ON, Canada
Background/Purpose: The systemic autoimmune rheumatic diseases (SARD; Systemic Lupus Erythematosus (SLE), Rheumatoid Arthritis (RA), Sjogren’s Disease (SjD), Systemic Sclerosis (SSc)) are proposed to have a…
Abstract Number: L22 • 2014 ACR/ARHP Annual Meeting
Long-Term (104-Week) Safety and Efficacy of Monotherapy with Apremilast in DMARD-Naïve Patients with Psoriatic Arthritis: A Phase 3, Randomized, Controlled Trial and Open-Label Extension (PALACE 4)
Alvin Wells¹, Christopher Edwards², Adewale O. Adebajo³, Alan J. Kivitz⁴, Paul Bird⁵, Kamal Shah⁶, ChiaChi Hu⁶, Randall M. Stevens⁶ and Jacob A. Aelion⁷, ¹Rheumatology & Immunotherapy Center, Franklin, WI, ²University Hospital Southampton, Southampton, United Kingdom, ³University of Sheffield, Sheffield, United Kingdom, ⁴Altoona Center for Clinical Research, Duncansville, PA, ⁵Combined Rheumatology Practice, Sydney, Australia, ⁶Celgene Corporation, Warren, NJ, ⁷West Tennessee Research Institute, Jackson, TN
Background/Purpose: Apremilast (APR) is an oral phosphodiesterase 4 inhibitor that helps regulate the immune response that causes joint inflammation and other manifestations of psoriatic arthritis…
Abstract Number: L3 • 2014 ACR/ARHP Annual Meeting
Low Protein A20 Expression in Minor Salivary Glands Is Associated with Lymphoma Development in Primary Sjögren’s Syndrome
Svein Joar A. Johnsen¹, Einar Gudlaugsson², Ivar Skaland², Emiel Janssen², Malin V. Jonsson³, Lars Helgeland⁴, Ellen Berget⁵, Roland Jonsson⁶ and Roald Omdal¹, ¹Clinical Immunology Unit, Department of Internal Medicine, Stavanger University Hospital, Stavanger, Norway, ²Stavanger University Hospital, Stavanger, Norway, ³Department of Clinical Dentistry - Section for Oral and Maxillofacial Radiology, University of Bergen, Bergen, Norway, ⁴Haukeland University Hospital, Bergen, Norway, ⁵University of Bergen, Bergen, Norway, ⁶Broegelmann Research Laboratory, Department of Clinical Science, University of Bergen, Bergen, Norway
Background/Purpose: Patients with primary Sjogrens syndrome (pSS) have an increased risk of developing lymphomas, especially of the subtype mucosa-associated lymphoid tissue (MALT) lymphoma. Chronic antigen…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].